Published in Neuro Oncol on January 26, 2016
Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption. J Control Release (2016) 0.76
Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors. Mol Ther Oncolytics (2016) 0.76
Focused Ultrasound: An Emerging Therapeutic Modality for Neurologic Disease. Neurotherapeutics (2017) 0.75
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol (2017) 0.75
Current and emerging brain applications of MR-guided focused ultrasound. J Ther Ultrasound (2017) 0.75
Treatment of Movement Disorders With Focused Ultrasound. J Cent Nerv Syst Dis (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci (2006) 12.23
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
The blood-brain barrier: bottleneck in brain drug development. NeuroRx (2005) 5.45
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery (2010) 3.15
Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains. Nat Cell Biol (2006) 3.08
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res (2009) 2.79
Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol (2004) 2.76
The management of brain metastases. Cancer Treat Rev (2003) 2.70
Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol (2007) 2.66
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia (1994) 2.65
Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res (2012) 2.60
Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol (2008) 2.47
Brain metastases. Histology, multiplicity, surgery, and survival. Cancer (1996) 2.31
Blood-brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology (2012) 1.64
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood (2002) 1.48
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol (2004) 1.44
Neurologic complications of chemotherapy agents. Curr Opin Neurol (2007) 1.39
The impact of standing wave effects on transcranial focused ultrasound disruption of the blood-brain barrier in a rat model. Phys Med Biol (2010) 1.37
Long-term survival with metastatic cancer to the brain. Med Oncol (2000) 1.21
Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery (2006) 1.18
Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release (2012) 1.18
Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Res (2013) 1.10
The role of caveolin-1 in blood-brain barrier disruption induced by focused ultrasound combined with microbubbles. J Mol Neurosci (2011) 1.03
Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol (1999) 0.98
Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol (2007) 0.96